Sinopharm Tech Holdings (HKSE:08156) Debt-to-EBITDA : 6.70 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sinopharm Tech Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sinopharm Tech Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$10.00 Mil. Sinopharm Tech Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$0.00 Mil. Sinopharm Tech Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$1.49 Mil. Sinopharm Tech Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 6.70.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sinopharm Tech Holdings's Debt-to-EBITDA or its related term are showing as below:

HKSE:08156' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.6 Med: -0.61 Max: 2.11
Current: -0.44

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sinopharm Tech Holdings was 2.11. The lowest was -3.60. And the median was -0.61.

HKSE:08156's Debt-to-EBITDA is ranked worse than
100% of 1616 companies
in the Software industry
Industry Median: 1.005 vs HKSE:08156: -0.44

Sinopharm Tech Holdings Debt-to-EBITDA Historical Data

The historical data trend for Sinopharm Tech Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Tech Holdings Debt-to-EBITDA Chart

Sinopharm Tech Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

Get a 7-Day Free Trial

-3.60

-0.85

-1.26

-0.61

Sinopharm Tech Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.91	-	-	-	6.70

Competitive Comparison of Sinopharm Tech Holdings's Debt-to-EBITDA

For the Software - Application subindustry, Sinopharm Tech Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Tech Holdings's Debt-to-EBITDA Distribution in the Software Industry

For the Software industry and Technology sector, Sinopharm Tech Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sinopharm Tech Holdings's Debt-to-EBITDA falls into.

Sinopharm Tech Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sinopharm Tech Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.829
	=	0.00

Sinopharm Tech Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(10	+	0)	/	1.492
	=	6.70

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Sinopharm Tech Holdings (HKSE:08156) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sinopharm Tech Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sinopharm Tech Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Tech Holdings (HKSE:08156) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ruttonjee Centre, 11 Duddell Street, Unit 1802, 18/F, Ruttonjee House, Hong Kong Central, Hong Kong, HKG

Website

https://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Ltd is an investment holding company. The company's operating segment includes Lottery-related services; Provision of Internet Plus services (solution and supply chain), Manufacturing and distribution of personal protective equipment, and Others services. It generates maximum revenue from the internet plus services (solution and supply chain) segment. The Internet plus Supply chain services segment includes the provision of supply chain management, data analysis and related services, and trading of goods through the internet platform. Geographically, it derives a majority of revenue from Hong Kong.

Executives

Best Frontier Investments Limited
Chan Kin Ho Philip	2201 Interest of corporation controlled by you
Lam Yui Keung	2201 Interest of corporation controlled by you
Sinopharm Traditional Chinese Medicine Overseas Holdings Limited	2101 Beneficial owner
Main Key Investments Limited	2201 Interest of corporation controlled by you
Guo Lei	2201 Interest of corporation controlled by you
Integrated Asset Management (asia) Limited	2101 Beneficial owner
Yam Tak Cheung	2201 Interest of corporation controlled by you
Chan Tung Mei	2202 Interest of your spouse
Cheung Kwai Lan	2201 Interest of corporation controlled by you
Tse Siu Hoi	2101 Beneficial owner
Gam Star China Equity (a Sub-fund Of Gam Star Fund P.l.c.)	2102 Investment manager

Sinopharm Tech Holdings (HKSE:08156) Headlines

No Headlines